Zenith Epigenetics Corp. is a biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and autoimmune disorders in targeted patient populations with significant unmet medical need. The company's cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Zenith‘s goal is to become a leading epigenetic company translating bromodomain biology into impactful therapies.
Zenith’s lead product is a pan selective BET inhibitor being developed for hematological malignancies and solid tumors. In Q4 2015, Zenith filed an IND for solid tumors with ZEN-3694. Phase 1 is expected to commence in the first half of 2016.
Our strong management team and organization allow us to efficiently and rapidly explore and progress these molecules from discovery to clinical development. Zenith’s research team, based in Calgary, Alberta, is well-positioned to take advantage of its broad and longstanding experience in epigenetics to become a leader in the discovery of selective BET inhibitors in both oncology and autoimmune diseases. The development activities are led by Zenith’s San Francisco based team, where a strong emphasis on translational medicine to drive patient pre-selection combined with a proven track record in drug development, will allow Zenith to excel in the field of epigenetics.